Rituximab for non-Hodgkin's lymphoma: a story of rapid success in translation.

Authors:
Dr Andrew M Harrison, MD, PhD
Dr Andrew M Harrison, MD, PhD
Mayo Clinic
Postdoctoral researcher
Clinical Informatics
Rochester, MN | United States
Nassir M Thalji
Nassir M Thalji
Mayo Clinic
United States
Alexandra J Greenberg
Alexandra J Greenberg
Mayo Clinic College of Medicine
United States
Carmen J Tapia
Carmen J Tapia
Mayo Clinic College of Medicine
United States
Anthony J Windebank
Anthony J Windebank
Mayo Clinic
United States

Clin Transl Sci 2014 Feb 3;7(1):82-6. Epub 2013 Oct 3.

Medical Scientist Training Program, Mayo Clinic, Rochester, Minnesota, USA.

Translational stories range from straightforward to complex. In this commentary, the story of the rapid and successful translation of rituximab therapy for the treatment of non-Hodgkin's lymphoma (NHL) is examined. Development of this monoclonal antibody therapy began in the late 1980s. In 1994, rituximab received its first approval for the treatment of NHL by the United States Food and Drug Administration (FDA). Rituximab has since been approved for additional indications and has transformed medical practice. However, the social and political implications of these rapid successes are only beginning to become clear. In this commentary, key events in the rapid translation of rituximab from the bench to bedside are highlighted and placed into this historical framework. To accomplish this, the story of rituximab is divided into the following six topics, which we believe to be widely applicable to case studies of translation: (1) underlying disease, (2) key basic science, (3) key clinical studies in translation, (4) FDA approval process, (5) changes to medical practice, and (6) the social and political influences on translation.

Download full-text PDF

Source
http://dx.doi.org/10.1111/cts.12111DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4264563PMC

Still can't find the full text of the article?

We can help you send a request to the authors directly.
February 2014
33 Reads
2.110 Impact Factor

Publication Analysis

Top Keywords

story rapid
8
studies translation
8
social political
8
translation rituximab
8
practice social
8
non-hodgkin's lymphoma
8
medical practice
8
translation
6
rituximab
6
rapid successes
4
implications rapid
4
political implications
4
clear commentary
4
rapid translation
4
rituximab bench
4
events rapid
4
key events
4
commentary key
4
successes clear
4
indications transformed
4

References

(Supplied by CrossRef)
Managing clinical knowledge for health care improvement
Balas et al.
Yearb Med Inform. 2000
Non-Hodgkin lymphoma
Shankland et al.
Lancet. 2012
Non-Hodgkin lymphoma: diagnosis and treatment
Ansell et al.
Mayo Clinic Proceedings. Mayo Clinic. 2005
Pathogenesis of non-Hodgkin's lymphoma
Nogai et al.
J Clin Oncol. 2011
Non-Hodgkin lymphoma: an update
Hennessy et al.
Lancet Oncol. 2004

Similar Publications